Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
15 May 2018 EMA Recommends a New Formulation and Extension of Indications for Dasatinib Haematologic malignancies - Anticancer agents & Biologic therapy
14 May 2018 FDA Grants Orphan Drug Designation for BN-Brachyury for the Treatment of Chordoma Sarcomas - Cancer Immunology and Immunotherapy
11 May 2018 Adolescent and Young Adults with Acute Lymphoblastic Leukaemia Benefit from Treatment in a Paediatric Setting or NCI-Designated Cancer Centre Haematologic malignancies - Cancer in Special Situations / Population
09 May 2018 Patients with Advanced TNBC Benefit from Characterisation of BRCA1/2 Mutations to Inform Choices on Platinum-Based Chemotherapy Breast cancer - Personalised medicine - Anticancer agents & Biologic therapy
08 May 2018 FDA Expends Approval for CAR-T Therapy, Tisagenlecleucel Haematologic malignancies - Cancer Immunology and Immunotherapy
08 May 2018 EMA Recommends Extension of Indications for Ipilimumab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
07 May 2018 FDA Approves Dabrafenib Plus Trametinib for Anaplastic Thyroid Cancer with BRAF V600E Mutation Endocrine and neuroendocrine tumours - Personalised medicine - Anticancer agents & Biologic therapy
04 May 2018 EMA Recommends Approval of Generic Carmustine Central nervous system malignancies - Haematologic malignancies - Anticancer agents & Biologic therapy
03 May 2018 Increased Germline and Tumour Mutation Testing Recommended in Adolescent and Young Adults with Cancer Cancer in Special Situations / Population - Personalised medicine
02 May 2018 FDA Approves Dabrafenib Plus Trametinib for Adjuvant Treatment of Melanoma with BRAF V600E or V600K Mutations, as Detected by an FDA-Approved Test Melanoma and other skin tumours - Anticancer agents & Biologic therapy
30 Apr 2018 EMA Recommends Extension of Indications for Osimertinib Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
30 Apr 2018 EMA Recommends Extension of Indications for Pertuzumab Breast cancer - Personalised medicine - Anticancer agents & Biologic therapy
27 Apr 2018 Poziotinib as a Clinically Active Inhibitor of EGFR and HER2 exon 20 mutations Lung and other thoracic tumours - Translational research - Anticancer agents & Biologic therapy
26 Apr 2018 Genetic Subtypes of DLBCL Uncovered Haematologic malignancies - Translational research
25 Apr 2018 Large National Sequencing Projects in Europe Personalised medicine